ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they're looking at the potential of an emerging cell technology to help in the fight against the recent virus outbreak.
Hunt also says the current disruption will inevitably lead to delays in the recruitment of patients to trials of its treatments for people with stroke disability and a degenerative eye condition called retinitis pigmentosa.
